By blocking the blood-vessel-tightening action of angiotensin II, telmisartan in Micardis lowers blood pressure. These prescription tablets are used for adults with essential hypertension and, in…
By blocking the blood-vessel-tightening action of angiotensin II, telmisartan in Micardis lowers blood pressure. These prescription tablets are used for adults with essential hypertension and, in selected high-risk adults unable to use ACE inhibitors, cardiovascular-risk reduction. Its once-daily action supports 24-hour blood-pressure control.
Micardis is an established telmisartan brand used to treat essential hypertension in adults. Essential hypertension means persistently raised blood pressure without a single identifiable cause. Lowering it reduces strain on the heart, brain, kidneys, and blood vessels.
Micardis tablets contain telmisartan, an angiotensin II receptor blocker, also called an ARB. ARBs lower blood pressure by reducing the effect of a hormone that narrows blood vessels and encourages the body to retain sodium.
Telmisartan is sometimes prescribed alone, as with Micardis, or as part of a regimen that includes a thiazide diuretic such as hydrochlorothiazide. Hydrochlorothiazide helps the kidneys remove sodium and water, which can add to blood-pressure lowering when one medicine alone is insufficient.
| Treatment approach | Active substance or class | Main clinical consideration |
|---|---|---|
| Micardis | Telmisartan, an ARB | Suitable when renin-angiotensin system blockade is needed |
| ACE inhibitor | ACE-inhibiting medicine | May cause a persistent dry cough in some people |
| ARB plus thiazide diuretic | Telmisartan-type ARB with hydrochlorothiazide | May improve control but needs closer electrolyte monitoring |
Combination treatment is not automatically stronger in the sense of being better for every person. It can lower blood pressure more, yet hydrochlorothiazide may also affect potassium, sodium, uric acid, and glucose levels.
Micardis is an established telmisartan brand used to treat essential hypertension in adults.
Telmisartan may also be used to reduce cardiovascular morbidity in adults with documented cardiovascular disease who cannot take an ACE inhibitor. The European Medicines Agency describes this use in adults at high cardiovascular risk, alongside blood-pressure management and other risk-reduction measures [1].
Micardis may be prescribed for:
Blood pressure rarely causes symptoms. Feeling well does not prove that it is controlled.
Take Micardis by mouth once daily at the prescribed strength. It may be taken with or without food, and the tablet should be swallowed whole with water. Dosing differs between strengths and between users, so there is no single amount that suits everyone.
A prescriber may adjust treatment after reviewing blood-pressure readings, kidney function, potassium levels, other medicines, and cardiovascular risk. People who are dehydrated, taking a diuretic, or starting treatment after severe vomiting or diarrhoea may be more prone to low blood pressure.
Common administration errors include:
Micardis is not suitable for every adult.
Clinical monitoring often includes:
The WHO guidance on hypertension stresses regular assessment of cardiovascular risk and organ function alongside medicine treatment [4].
This is NOT for you if you are pregnant, have a known allergy to telmisartan or tablet ingredients, or have biliary obstructive disorders or severe hepatic impairment.
Avoid Micardis during the second and third trimesters of pregnancy. Medicines acting on the renin-angiotensin system can damage fetal kidney development and reduce amniotic fluid. Treatment should be discontinued as soon as pregnancy is detected, with a prescriber selecting an alternative blood-pressure treatment.
Breastfeeding use is generally avoided because better-studied alternatives may be preferred for infants. Telmisartan also requires careful use in renal artery stenosis, severe heart failure, advanced kidney impairment, or situations that reduce circulating blood volume.
Micardis is usually well tolerated, though no blood-pressure treatment is free from adverse effects. Dizziness can occur, especially near the start of treatment or after a dose adjustment. It may reflect a useful reduction in blood pressure, yet it can also mean that the pressure has fallen too far for that person.
Possible effects associated with telmisartan include dizziness, low blood pressure, raised potassium, changes in kidney function, tiredness, and back pain. Serious allergic reactions are uncommon but require urgent medical assessment if swelling of the face, lips, tongue, or throat occurs.
A regimen that includes hydrochlorothiazide has extra considerations. Thiazide diuretics may cause low sodium or potassium, dehydration, gout flare-ups, increased uric acid, and sensitivity to sunlight. They can also alter blood glucose in susceptible people.
The FDA prescribing information for telmisartan identifies hypotension, hyperkalaemia, and renal-function changes as clinically relevant risks in susceptible patients [3].
Telmisartan is a selective AT1 angiotensin II receptor antagonist. Angiotensin II normally binds to AT1 receptors in blood vessels, the adrenal glands, kidneys, and heart. That signal narrows vessels and stimulates aldosterone release, which promotes sodium and fluid retention.
By occupying AT1 receptors, telmisartan reduces these effects. Blood vessels relax, peripheral resistance falls, and blood pressure decreases without directly slowing the heart rate. The effect develops smoothly rather than causing an immediate dramatic drop in most people.
ARBs differ from ACE inhibitors because they block the angiotensin II receptor rather than reducing angiotensin II formation. This distinction explains why ARBs are less likely to cause the dry cough associated with ACE inhibitor therapy.
Micardis controls blood pressure but does not remove the need to address smoking, excess salt intake, inactivity, diabetes, or high cholesterol when those factors are present.
Doctors usually assess treatment by repeated blood-pressure readings, kidney function, and blood potassium rather than by symptoms alone. A person may feel exactly the same while their readings improve substantially.
The HPRA Summary of Product Characteristics for telmisartan describes once-daily use and sustained antihypertensive activity [2].
One frequent mistake is treating Micardis as a tablet only for days when blood pressure appears high. Telmisartan works best when taken consistently, because the aim is stable 24-hour control rather than short-term correction.
Another is assuming that dizziness always means the medicine is wrong. A new dizzy spell can result from dehydration, alcohol, heat, another blood-pressure medicine, or a genuine low reading. The useful next step is a properly taken blood-pressure reading and timely clinical review.
People also overlook over-the-counter painkillers. Regular use of ibuprofen, naproxen, or similar anti-inflammatory medicines can place extra pressure on the kidneys when combined with an ARB, especially during dehydration.
Micardis is an oral, once-daily telmisartan treatment that lowers blood pressure by blocking angiotensin II; it differs mechanistically from ACE-inhibitor treatment and may support cardiovascular-risk reduction in selected adults unable to use an ACE inhibitor.
In clinical practice, doctors focus less on one isolated blood-pressure number and more on the pattern across weeks. Micardis is valued for once-daily dosing and a lower likelihood of ACE inhibitor-related cough. It is often a sensible option when an ACE inhibitor has caused cough or has not been tolerated.
The limitation is that blood-pressure treatment needs follow-up. Kidney function and potassium can change after starting treatment, increasing the dose, adding a diuretic, or becoming dehydrated. People with diabetes, chronic kidney disease, heart failure, or several antihypertensive medicines often need closer monitoring.
A once-daily dose is designed to provide blood-pressure lowering throughout a 24-hour interval. Telmisartan has a long action, which is why it is commonly taken once per day rather than several times daily. The EMA product information published in 2023 describes sustained antihypertensive activity with daily administration. A missed dose should not be compensated for by taking extra tablets.
Micardis is intended for adult use. Its safety and effectiveness for hypertension in children and adolescents have not been established in the same way as for adults. The 2023 EMA product information does not recommend routine paediatric use. A paediatric hypertension specialist should select treatment for anyone under 18.
Take the missed tablet when remembered on the same day, unless the next scheduled dose is due soon. If it is nearly time for the next dose, skip the missed tablet and return to the usual once-daily schedule. Do not take two tablets together. The HPRA telmisartan prescribing information, reviewed in 2024, supports maintaining the normal schedule rather than doubling doses.
Micardis tablets should be swallowed whole with water. Crushing or chewing can make an unpleasant-tasting medicine harder to take and may affect reliable administration. Splitting should only be done when a prescriber or pharmacist has specifically confirmed that the prescribed tablet is suitable for splitting. The EMA product information from 2023 describes oral tablet administration as swallowing the tablet with liquid.
Alcohol can add to blood-pressure lowering and make dizziness, faintness, or poor balance more likely. This is most relevant when treatment has recently started, after a dose adjustment, during hot weather, or when fluid intake has been low. The WHO hypertension guidance updated in 2023 identifies alcohol reduction as part of cardiovascular risk management. People who drink should avoid using alcohol to excess and should be cautious if they notice postural dizziness.
Treatment for hypertension is commonly long term because raised blood pressure usually returns when treatment stops. Micardis may be continued for years when blood pressure, kidney function, and potassium remain appropriately monitored. NICE guidance updated in 2023 treats hypertension as a chronic cardiovascular-risk condition that requires ongoing review. A prescriber may adjust therapy when health status, laboratory results, or other medicines change.
Pregnancy rules out Micardis because telmisartan can harm fetal kidney development, especially after the first trimester. If pregnancy is detected while using it, treatment should be stopped promptly and an alternative selected by the prescriber. The FDA telmisartan prescribing information from 2018 carries a fetal-toxicity warning for medicines acting on the renin-angiotensin system. Anyone planning pregnancy should discuss a suitable alternative before conception.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
I took Micardis each morning for four months after my home readings stayed high. The first week brought mild light-headedness when I stood up too fast, then it settled. My readings became more even, and I liked not having the dry cough I had with my previous treatment.
Four months 10 Oct 2026My blood pressure improved over the first month, but I made the mistake of checking it straight after gardening and thought the tablets were failing. My GP asked me to rest before measuring. The calmer readings were much lower.
The first month 19 Oct 2026I used Micardis for nearly six months and had no obvious side effects. The part I found difficult was remembering it on weekends, so I moved it beside my breakfast bowl. My blood tests were checked after starting, which reassured me.
Nearly six months 27 Oct 2026I felt dizzy after a bout of diarrhoea and had lower readings than usual. It was annoying because I had assumed it was just the tablet. After speaking with my prescriber, I understood that dehydration was part of the problem.
5 Nov 2026
